Depth of Neuromuscular Blockade and the Perioperative Conditions in Laparoscopic Surgery in Pediatric Population

Summary

This randomized study prospectively evaluates our experience with administration of cisatracurium and rocuronium antagonized by sugammadex and evaluates the effects of various depths of neuromuscular blockage on providing optimal surgical conditions during laparoscopy with low-pressure capnoperitoneum.

Conditions

• Neuromuscular Blockade

Interventions

DRUG

Rocuronium

rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)

DRUG

Cisatracurium

cisatracurium 0.15mg/kg intravenously

DRUG

Nonspecific Neuromuscular Blockade reversal

neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously

DRUG

Specific Neuromuscular Blockade reversal

Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered

DRUG

maintaining the depth of neuromuscular blockade - rocuronium

repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1

DRUG

maintaining the depth of neuromuscular blockade - cisatracurium

repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1

Sponsors & Collaborators

• KDCHOT FN Brno

  collaborator UNKNOWN

• Brno University Hospital

  lead OTHER

Principal Investigators

• Petr Štourač, MD, Ph.D · KDAR FN Brno

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

2 Years

Max Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-12-31

Primary Completion

2018-09-30

Completion

2019-05-31

Countries

• Czechia

Study Locations